JP2021521119A5 - - Google Patents

Info

Publication number
JP2021521119A5
JP2021521119A5 JP2020555099A JP2020555099A JP2021521119A5 JP 2021521119 A5 JP2021521119 A5 JP 2021521119A5 JP 2020555099 A JP2020555099 A JP 2020555099A JP 2020555099 A JP2020555099 A JP 2020555099A JP 2021521119 A5 JP2021521119 A5 JP 2021521119A5
Authority
JP
Japan
Prior art keywords
acid
buffer
chromatography
ultrafiltration
antibody construct
Prior art date
Application number
JP2020555099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521119A (ja
JP7465215B2 (ja
JPWO2019199476A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/024683 external-priority patent/WO2019199476A1/en
Publication of JP2021521119A publication Critical patent/JP2021521119A/ja
Publication of JP2021521119A5 publication Critical patent/JP2021521119A5/ja
Publication of JPWO2019199476A5 publication Critical patent/JPWO2019199476A5/ja
Priority to JP2024056116A priority Critical patent/JP2024075786A/ja
Application granted granted Critical
Publication of JP7465215B2 publication Critical patent/JP7465215B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020555099A 2018-04-12 2019-03-28 安定なタンパク質組成物を製造する方法 Active JP7465215B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024056116A JP2024075786A (ja) 2018-04-12 2024-03-29 安定なタンパク質組成物を製造する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656687P 2018-04-12 2018-04-12
US62/656,687 2018-04-12
PCT/US2019/024683 WO2019199476A1 (en) 2018-04-12 2019-03-28 Methods for making stable protein compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024056116A Division JP2024075786A (ja) 2018-04-12 2024-03-29 安定なタンパク質組成物を製造する方法

Publications (4)

Publication Number Publication Date
JP2021521119A JP2021521119A (ja) 2021-08-26
JP2021521119A5 true JP2021521119A5 (https=) 2022-03-30
JPWO2019199476A5 JPWO2019199476A5 (https=) 2022-03-30
JP7465215B2 JP7465215B2 (ja) 2024-04-10

Family

ID=66251859

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020555099A Active JP7465215B2 (ja) 2018-04-12 2019-03-28 安定なタンパク質組成物を製造する方法
JP2024056116A Pending JP2024075786A (ja) 2018-04-12 2024-03-29 安定なタンパク質組成物を製造する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024056116A Pending JP2024075786A (ja) 2018-04-12 2024-03-29 安定なタンパク質組成物を製造する方法

Country Status (15)

Country Link
US (1) US20210163531A1 (https=)
EP (1) EP3774894A1 (https=)
JP (2) JP7465215B2 (https=)
KR (1) KR102791798B1 (https=)
CN (1) CN111971302A (https=)
AU (2) AU2019250882B2 (https=)
BR (1) BR112020020854A2 (https=)
CA (1) CA3096374A1 (https=)
CL (1) CL2020002597A1 (https=)
EA (1) EA202092464A1 (https=)
IL (1) IL277797B1 (https=)
MA (1) MA52204A (https=)
MX (2) MX2020010724A (https=)
SG (1) SG11202010100QA (https=)
WO (1) WO2019199476A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150210753A1 (en) 2012-07-26 2015-07-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
AU2020381536A1 (en) * 2019-11-13 2022-04-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
WO2021252782A1 (en) * 2020-06-11 2021-12-16 2Seventy Bio, Inc. Methods for manufacturing viral vectors
US12286451B2 (en) 2020-11-23 2025-04-29 Medtech Products Inc. Borate ester complexes of α-hydroxy carboxylic acids and their conjugate base buffers
US20240101679A1 (en) * 2020-12-09 2024-03-28 Dr. Reddy’S Laboratories Limited Stable aqueous buffer free formulation of an integrin antibody
WO2024165043A1 (en) * 2023-02-08 2024-08-15 Beigene Switzerland Gmbh Preparation methods for a highly concentrated pd1 antibody solution by applying single-pass tangential flow filtration (sptff)
CN117088974B (zh) * 2023-08-14 2024-02-13 武汉健昊生物科技有限公司 一种抗体保存液
CN121587349A (zh) * 2026-01-28 2026-03-03 内蒙古蒙牛乳业(集团)股份有限公司 高浓度无菌乳铁蛋白液及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005323489A1 (en) * 2004-05-10 2006-07-13 Curagen Corporation Prophylactic and therapeutic uses of FGF-20 in radiation protection
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
CN101098889A (zh) 2004-11-05 2008-01-02 盘林京有限公司 抗体导致的细胞膜损伤
AU2006270009A1 (en) 2005-07-18 2007-01-25 Amgen Inc. Human anti-B7RP1 neutralizing antibodies
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
ES2650224T3 (es) 2007-08-21 2018-01-17 Amgen, Inc. Proteínas de unión al antígeno C-FMS humano
US20130195888A1 (en) * 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
TWI543768B (zh) * 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
HUE025670T2 (en) * 2009-03-03 2016-04-28 Grifols Therapeutics Inc A method for producing plasminogen
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
CA2810731A1 (en) * 2010-09-17 2012-03-22 Baxter International Inc. Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral ph
AU2012250924B2 (en) * 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
ES2381828B1 (es) * 2012-03-20 2012-11-16 Grifols, S.A. PROCEDIMIENTO PARA OBTENER UNA COMPOSICION DE IgG MEDIANTE TRATAMIENTO TERMICO
US20140154270A1 (en) * 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
AU2014205441B2 (en) * 2013-01-09 2019-12-12 Takeda Pharmaceutical Company Limited Methods for purification of arylsulfatase A
CA2906737C (en) 2013-03-15 2023-08-15 Amgen Inc. Human pac1 antibodies
EP3102603A1 (en) * 2014-02-07 2016-12-14 Novo Nordisk A/S Antibody process
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
SG11201901081XA (en) * 2016-08-17 2019-03-28 Boehringer Ingelheim Int Process for the preparation of highly concentrated liquid formulations containing biomolecules
GB201707484D0 (en) * 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies
EP3446710A1 (en) * 2017-08-25 2019-02-27 Glenmark Pharmaceuticals S.A. Methods of inactivating viral contaminants
GB2636539A (en) * 2023-03-16 2025-06-25 Univ Of Sunderland Wound dressing

Similar Documents

Publication Publication Date Title
JP2021521119A5 (https=)
AU2026200233A1 (en) Methods for making stable protein compositions
TWI459961B (zh) 長效人類生長激素共軛物之液態配方
JP5153532B2 (ja) モノクローナル抗体又はポリクローナル抗体の安定な凍結乾燥された医薬製剤
EP2485766B1 (fr) Excipient stabilisant pour vaccins a virus entiers inactifs
JP2020079242A (ja) 高濃度の抗vegf抗体を含有する安定状態のタンパク質溶液製剤
KR101335765B1 (ko) 지속형 에리스로포이에틴 결합체의 액상 제제
EP2258402A2 (en) Dried composition
NZ286046A (en) Stable transglutaminase (factor xiii) preparations
US8216588B2 (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
JP2021503485A (ja) VEGFR−Fc融合タンパク質製剤
JPWO2019199476A5 (https=)
CN114288254A (zh) 长效人生长激素缀合物的制剂
KR20150074167A (ko) Peg 인터페론 알파-2b의 안정한 약학 조성물
CN103611162B (zh) 人凝血因子ⅷ冻干保护剂及其制备方法
CA3168727A1 (en) Daptomycin formulation with branched aiphatic amino acid
Prasad et al. Innovation in stabilization of biopharmaceuticals
US20250312436A1 (en) Stabilization of virus-based therapeutic agent
WO2025226754A1 (en) Method for predicting osmolality of protein solutions
CA2966758C (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
KR19990075253A (ko) 약학적으로 안정한 인터페론 제
MXPA01002206A (en) Stabilized granulocyte colony stimulating factor